---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-025573"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:02:29.631079+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AbCellera gets Health Canada nod for Phase 1 trial of ABCL635 for hot flashes

## Summary
- Received No Objection Letter from Health Canada for ABCL635, an NK3R antagonist for non-hormonal treatment of vasomotor symptoms.
- Phase 1 trial to evaluate safety, PK, and PD in healthy participants and postmenopausal women with moderate-to-severe VMS.
- Trial expected to begin in Q3 2025.
- ABCL635 is an investigational antibody antagonist targeting NK3R, developed for hot flashes due to menopause.

## SEC filing metadata
- accession: 0001628280-25-025573
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000162828025025573/0001628280-25-025573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000162828025025573/abcl-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-025573
- JSON: https://secwatch.observer/filing/0001628280-25-025573.json
- Plain text: https://secwatch.observer/filing/0001628280-25-025573.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.